Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics

In its upcoming report, 10x Genomics (TXG) is predicted by Wall Street analysts to post quarterly loss of $0.47 per share, reflecting an increase of 11.3% compared to the same period last year. Revenues are forecasted to be $150.9 million, representing a year-over-year increase of 2.8%. The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial ...